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BACKGROUND: XIAP (X-linked inhibitor of apoptosis protein) is an anti-apoptotic protein exerting its activity by binding and
suppressing caspases. As XIAP is overexpressed in several tumours, in which it apparently contributes to chemoresistance, and
because its activity in vivo is antagonised by second mitochondria-derived activator of caspase (SMAC)/direct inhibitor of apoptosis-
binding protein with low pI, small molecules mimicking SMAC (so called SMAC-mimetics) can potentially overcome tumour
resistance by promoting apoptosis.
METHODS: Three homodimeric compounds were synthesised tethering a monomeric SMAC-mimetic with different linkers and their
affinity binding for the baculoviral inhibitor repeats domains of XIAP measured by fluorescent polarisation assay. The apoptotic
activity of these molecules, alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or
Bortezomib, was tested in melanoma cell lines by MTT viability assays and western blot analysis of activated caspases.
RESULTS: We show that in melanoma cell lines, which are typically resistant to chemotherapeutic agents, XIAP knock-down sensitises
cells to TRAIL treatment in vitro, also favouring the accumulation of cleaved caspase-8. We also describe a new series of 4-substituted
azabicyclo[5.3.0]alkane monomeric and dimeric SMAC-mimetics that target various members of the IAP family and powerfully
synergise at submicromolar concentrations with TRAIL in inducing cell death. Finally, we show that the simultaneous administration of
newly developed SMAC-mimetics with Bortezomib potently triggers apoptosis in a melanoma cell line resistant to the combined
effect of SMAC-mimetics and TRAIL.
CONCLUSION: Hence, the newly developed SMAC-mimetics effectively synergise with TRAIL and Bortezomib in inducing cell death.
These findings warrant further preclinical studies in vivo to verify the anticancer effectiveness of the combination of these agents.
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Members of the IAP (inhibitor of apoptosis protein) family are key
regulators of apoptosis and of clinical prognostic value in cancer
(Kempkensteffen et al, 2007). Together with cellular IAP (cIAP)
1 and 2, XIAP (X-linked IAP) is one of the three most studied IAPs.
The structure of XIAP is characterised by three N-terminal tandem
repeat domains, called BIRs (baculoviral inhibitor repeats),
peculiar of the IAP family, and a C-terminal RING (really
interesting new gene) finger, endowed with E3 ubiquitin-ligase
function. XIAP is a major negative regulator of apoptosis, a
property dependent on its BIR domains (Takahashi et al, 1998)
that bind to and inhibit both initiator caspase-9 and effector
caspases 3 and 7 (Deveraux et al, 1997). cIAP1 and cIAP2, also
bind caspases (Eckelman and Salvesen, 2006) but the biological
significance of this interaction is less well understood. XIAP can
regulate caspases and other proteins, not only by binding and
sequestering them, but also by ubiquitination and consequent
proteasome-dependent degradation.
The activity of XIAP is antagonised by SMAC/DIABLO (second
mitochondria-derived activator of caspase/direct inhibitor of
apoptosis-binding protein with low pI), that, on release from
mitochondria in response to apoptotic stimuli (Du et al, 2000),
undergoes maturation and cleavage of its N-terminal region,
allowing the exposure of the AVPI sequence. This tetrapeptide
binds XIAP (Wu et al, 2000) and competes with the same binding
sites that are responsible for the interaction with caspases
(Liu et al, 2000). In this way, SMAC/DIABLO prevents the
sequestration of caspases, facilitating the apoptotic pathway.
As the AVPI sequence can promote apoptosis, compounds
mimicking this tetrapeptide, called SMAC-mimetics, have become
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sthe focus of intense research (Li et al, 2004; Oost et al, 2004;
Mastrangelo et al, 2008) as pro-apoptotic pharmacological agents
for cancer treatment (Sun et al, 2006). Accordingly, several
XIAP-targeting SMAC-mimetics have been developed. Intrigu-
ingly, they were also found to target other members of the IAP
family, especially cIAP1 and cIAP2 (Varfolomeev et al, 2007;
Vince et al, 2007; Galba ´n et al, 2009). To improve their activity,
dimeric SMAC-mimetics formed by two binding heads tethered
by a chemical linker, were recently generated and shown to be
more potent than the monomeric counterparts (Li et al, 2004;
Lu et al, 2008) because of the simultaneous binding to two BIR
domains (Cossu et al, 2009b).
In some cell lines, SMAC-mimetics as single agents elicit cell
death through the extrinsic apoptotic pathway (Gaither et al, 2007)
triggered by autocrine production of tumour necrosis factor (TNF)
(Petersen et al, 2007; Varfolomeev et al, 2007; Vince et al, 2007;
Wang et al, 2008) and requiring caspase-8 activation (Bertrand
et al, 2008). In the vast majority of cancer cells, however,
SMAC-mimetics as single agents are poorly cytotoxic (Petersen
et al, 2007), although they can potently synergise with the
apoptosis-inducing ligands of the TNF superfamily (Li et al,
2004). Although TNF and CD95 ligand (CD95L/FasL) are
unsuitable for cancer treatment because of their systemic
inflammatory effects (Lejeune et al, 1998) and hepatotoxicity
(Walczak et al, 1999), respectively, the TNF-related apoptosis-
inducing ligand (TRAIL) is an extremely promising biotherapeutic,
owing to its potency and limited side effects (Ashkenazi and
Herbst, 2008). In spite of the fact that 50% of tumour cell lines are
TRAIL-sensitive, it was recently shown that primary tumour cells
derived from human breast, lung and colon tumours are often
TRAIL-resistant (Todaro et al, 2008). Although TRAIL has been
suggested for treatment of melanoma (Kurbanov et al, 2005), a
tumour typically resistant to chemotherapy, also melanomas are
often unresponsive to TRAIL-induced apoptosis (Kurbanov et al,
2006). Therefore, it is important to identify drugs, which when
used in combination with TRAIL, can overcome this resistance.
In this study, we show that human melanoma cell lines can be
sensitised to TRAIL in vitro by knocking down XIAP by shRNA
interference. Furthermore, Bortezomib, a proteasome inhibitor
currently used in cancer treatment, can also sensitise melanoma
cells to TRAIL. Finally, we describe new SMAC-mimetic com-
pounds, synthesised on the basis of structure-based approaches
that markedly synergise with TRAIL in killing melanoma cells.
MATERIALS AND METHODS
Cell culture and reagents
All the cell lines (Me1007, Me4405, Me10538, Me2211M2, MDA-
MB231) were maintained in RPMI plus 10% fetal calf serum.
Bortezomib (Velcade) was kindly provided by Professor Carlostella,
isoleucine zipper (iz)-TRAIL was produced as described (Ganten
et al, 2006). SMAC-mimetics were synthesised at the CISI Institute.
The primary antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA) (cleaved caspase-3 and cleaved
PARP), Alexis Biochemicals (San Diego, CA, USA) (cFLIP, caspase-8),
BD Biosciences (San Jose, CA, USA) (XIAP and cIAP2), Sigma (St
Louis, MO, USA) (b-Actin) and R&D Systems (Minneapolis, MN,
USA) (cIAP1). ECL-HRP linked secondary antibodies were from GE
Healthcare (Piscataway, NJ, USA). siCASP8 SMARTpool was
purchased from Dharmacon (Lafayette, CO, USA), z-vad-fmk from
BIOMOL Int (Plymouth Meeting, PA, USA).
Cell proliferation and apoptosis
Cell proliferation was determined by the MTT assays on cells
seeded in 96-well culture plates (10000cells per well) with 100mlo f
medium, treated 24h later with drugs and incubated for further
72h. MTT absorbance was read with a plate reader (Tecan Genios,
Tecan US, Durham, NC, USA) at a wavelength of 495nM. The blank
value was subtracted from each measurement and the percentage
of viability was determined by comparison with untreated cells.
Apoptotic cells with a sub-diploid G1 content were quantitated by
flow cytometry on samples that after treatment with drugs, were
harvested, fixed in 70% ethanol, treated with RNAse and stained
with propidiun iodide. Sub-G1 population was then revealed with a
FACS-Scan (Becton Dickinson, San Jose, CA, USA).
Western blot analysis
Cells were lysed in SDS/Tris-HCl and fractionated on SDS–PAGE.
Proteins were blotted on PVDF membranes, saturated with non-fat
dry milk and incubated overnight with the indicated primary
antibody. After washing, the membranes were exposed to the
appropriate secondary antibody for 1h and finally the proteins of
interest were detected by ECL (Pierce, Rockford, IL, USA).
Recombinant protein purification
pET28 XIAP-Bir3 and XIAP-lkBir2Bir3 were used to produce the
recombinant proteins for the binding assay (Mastrangelo et al,
2008). The plasmids were used to transform Escherichia coli strain
BL21(DE3) and induced with 1mM of IPTG. Bacteria grown in LB
medium plus kanamycin and 50mM zinc acetate were harvested,
resuspended in a buffer containing 50mM Tris-HCl, pH 7.5,
200mM NaCl and protease inhibitors, treated with 100mgml
–1
lysozyme for 30min on ice, and then lysed by sonication. After
elimination of debris by centrifugation, recombinant protein was
purified using Ni-NTA (His-trap FFcrude, GE Healthcare),
followed by gel filtration (Superdex 200, GE Healthcare). The
recombinant proteins were eluted with 250mM imidazole
and thereafter stored in 20mM Tris, pH 7.5, 200mM NaCl and
10mM DTT.
Binding assays
Fluorescent polarisation-based binding assay was performed as
described before (Mastrangelo et al, 2008; Cossu et al, 2009b).
Briefly, two saturation curves were obtained by adding increasing
concentrations of recombinant XIAP-BIR3 (241–356) or XIAP-
lkBIR2BIR3 (124–356) to a fixed quantity of a fluorescent mono-
meric or dimeric SMAC-mimetic, respectively. The Kd was
measured and used to determine the concentration of probe to
be used in the competition experiment, in which SMAC-mimetics
were added at rising concentrations. All data were plotted using
Graphpad (San Diego, CA, USA).
XIAP knock-down
XIAP knock-down was obtained by RNA interference using
lentiviral vectors (Invitrogen, Carlsbad, CA, USA). Lentiviruses
were produced in accordance to the manufacturer’s instructions.
In all, 293FT cells were transfected with ViraPower (Invitrogen)
plus a pLenti vector carrying a sequence for XIAP RNA
interference (Kashkar et al, 2007) or a control sequence (shLac),
using Lipofectamine2000 (Invitrogen). The following day the
medium was substituted and then collected after 24h, clarified
from cellular debris by centrifugation and added to the cells of
interest. Transduced clones were selected by adding blasticidin to a
final concentration of 6mgml
–1.
Synthesis of SMAC-mimetics
The synthesis of monomeric SMAC067 has already been reported
by us (Seneci et al, 2009), while the synthesis of the dimeric
SMAC-mimetics sensitise melanoma cells
D Lecis et al
1708
British Journal of Cancer (2010) 102(12), 1707–1716 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
scompounds SMAC074, SMAC075 and SMAC076 (Supplementary
Figure S2) will be reported in a forthcoming paper (P Seneci,
C Battaglia, L Belvisi, M Bolognesi, A Caprini, F Cossu, M de Matteo,
D Delia, C Drago, D Lecis, L Manzoni, M Marizzoni, E Mastrangelo,
M Milani, E Moroni, D Potenza, V Rizzo, F Servida, F Vasile and
C Scolastico, 2010, to be submitted).
RESULTS
TRAIL sensitivity in melanoma cell lines
We evaluated the sensitivity of the well-characterised melanoma
cell lines Me4405, Me10538, Me2211M2 and Me1007 derived from
patients of our institute, to increasing concentrations of iz-TRAIL.
The proliferation of Me4405, Me10538 and Me2211M2 was
inhibited by TRAIL in a dose-dependent manner, while Me1007
cells were resistant to this drug (Supplementary Figure S1) in
keeping with the their low expression of caspase-8 (Zhang et al,
2001), a key mediator of the extrinsic apoptosis pathway
(Chen et al, 2008). TRAIL-induced apoptosis was accompanied
by cleavage of PARP, strongly detectable in all the lines except
Me1007 (Figure 1), and by activation of caspase-8 yielding the
cleaved p41 and 43 forms. These two bands were undetectable in
Me1007 but evident in the other cell lines, and accompanied by
the reduction of full-length caspase-8 (Figure 1). Caspase-8 cleaves
and activates the effector caspase-3, whose cleaved forms were
detectable in all lines tested after treatment with iz-TRAIL. We also
analysed the response to Bortezomib and compound-3, a dimeric
SMAC-mimetic (Li et al, 2004), but these agents had little effect,
if any, in activating apoptosis at the doses used (Figure 1).
Altogether, iz-TRAIL kills melanoma cells by activating the
extrinsic apoptosis pathway involving caspase-8, -3 and PARP
cleavage. This pathway is associated with caspase-8, whose faint
levels in Me1007 preclude their responsiveness.
Downregulation of XIAP is sufficient to restore TRAIL
sensitivity even in melanoma cells with low expression
of caspase-8
As sensitisation of tumour cells to TRAIL can be achieved by
downregulating XIAP (Vogler et al, 2008), we asked whether
a similar response could be induced in Me1007 cells, in spite
of their low expression of caspase-8. We therefore generated
Me1007 cells stably expressing an shRNA-targeting XIAP or a
control sequence (shLac) as negative control. Interestingly, XIAP
knock-down restored TRAIL sensitivity in Me1007 (Figure 2A)
and this was not cell-type specific because a similar phenomenon
was observed in the mammary carcinoma cell line MDA-MB231
(Figure 2B). The treatment with 50ngml
–1 iz-TRAIL for 24h
resulted in the accumulation of the p43/41 form of caspase-8
in MDA-MB231 (Figure 2C right) but not in Me1007 cells
(Figure 2C left). Furthermore, this accumulation was evident
in cells with downregulated levels of XIAP and not in control
cells expressing the scrambled sequence (shLac, Figure 2C
right). Interestingly, TRAIL treatment induced the downregu-
lation of XIAP also in control cells. Cleaved caspase-8 was
detectable in Me1007 cells after 6h of treatment only in response
to doses of iz-TRAILX1mgml
–1, and even so the p43/41 form
was evident only in cells with downregulated levels of XIAP
(Figure 2D).
Thus, XIAP contributes to the resistance of melanoma cells to
TRAIL and its downregulation favours the extrinsic apoptotic
pathway.
Bortezomib sensitises melanoma cells without affecting
caspase-8 expression levels
The proteasome inhibitor Bortezomib (Velcade/PS-341) is an
effective drug in the treatment of multiple myeloma and other
– + – – – Comp3
+ – + – – Bortez
+ – – + TRAIL
Me1007
Cleaved
PARP
Caspase-8
Cleaved caspase-8
β-Actin
Cleaved caspase-3
– + – – – Comp3
+ – + – – Bortez
+ – – + – TRAIL
Me4405
Cleaved
PARP
Caspase-8
Cleaved caspase-8
β-Actin
Cleaved caspase-3
– +
–
– – – Comp3
+ – + – – Bortez
+ – – + – TRAIL
Me10538
– + – – – Comp3
+ – + – – Bortez
+ – – + – TRAIL
Me2211M2
p89
p55
p43/41
p17/19
p89
p55
p43/41
p17/19
Figure 1 Sensitivity of melanoma cell lines to TRAIL, Bortezomib and SMAC-mimetics. Levels of cleaved PARP, caspase-3, caspase-8 or full-length
caspase-8 in melanoma cells treated for 24h with 50ngml
–1iz-TRAIL, 5nM Bortezomib (4nM in the case of Me1007) or 500nM compound 3 or mock-
treated. b-Actin is used as loading control.
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stumours, mainly functioning by inhibition of the NF-kB survival
pathway (reviewed by Boccadoro (Boccadoro et al, 2005)). Besides,
it sensitises tumour cells to other agents, including TRAIL
(Koschny et al, 2007). To determine whether Bortezomib
potentiates the activity of TRAIL also in melanoma cells, we first
tested it alone and found that at 4–5nM it inhibits the growth of
all melanoma cell lines. Significantly, the combination of TRAIL
with Bortezomib markedly increased loss of cell viability in all
melanoma lines (Figure 3A), paralleled by a rise in cleaved PARP
(Figure 1).
Two inducers of endoplasmic reticulum (ER) stress, Thapsigar-
gin and Tunicamycin, have been suggested to sensitise Me1007 to
TRAIL by upregulation of TRAIL-R2 (Chen et al, 2007; Jiang et al,
2007) and caspase-8 (Chen et al, 2008). As Bortezomib can also
cause ER stress (Boccadoro et al, 2005), we checked whether it
upregulated caspase-8 in Me1007, but no evidence for this was
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Figure 2 Role of XIAP in TRAIL resistance. Isogenic Me1007 (A) or MDA-MB231 (B) cell lines with normal (shLac) or downregulated levels of XIAP
were treated with serial dilutions of iz-TRAIL. Cell proliferation was measured after 72h by MTT assay. The figure is representative of three independent
experiments carried out in triplicate (mean values±s.d.). (C) Levels of cleaved or full-length caspase-8 in Me1007 (left) or MDA-MB231 (right) with knock-
down or normal levels of XIAP, treated or untreated with 50ngml
–1for 24h. Arrow indicates the p43/41 forms of caspase-8. b-Actin is used as loading
control. (D) Levels of caspase-8 and p43/41 caspase-8 in Me1007 with normal or knock-down XIAP, treated with 1mgml
–1 iz-TRAIL for 6h.
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sobserved, even in response to elevated doses of Bortezomib
(Figure 3B). As the accumulation of procaspase-8 could be
masked by its concomitant cleavage into the active forms,
cells were pretreated with the pan caspase inhibitor z-VAD-fmk,
which blocks caspase-8 cleavage. The treatment prevented caspase
activation, as revealed by inhibition of PARP cleavage (Figure 3C),
but did not affect the levels of caspase-8. Interestingly, treatment
with Bortezomib at a concentration of 50nM caused the accumu-
lation of the p43/41 form of caspase-8 (Figure 3B). Altogether,
these findings show that Bortezomib sensitises melanoma lines to
TRAIL without affecting the caspase-8 levels.
New SMAC-mimetics targeting the BIR2 and BIR3 domains
of XIAP
Recently, we have described a group of 4-substituted azabicyclo
[5.3.0]alkane SMAC-mimetics with submicromolar binding affinity
for XIAP. We showed that the introduction of a new chemical
arm in position 4 actually favoured the establishment of new
interactions between the SMAC-mimetics and the BIR domains of
XIAP (Mastrangelo et al, 2008; Cossu et al, 2009a), strengthening
the binding of our compounds to the target protein. The SMAC-
mimetic molecules were first modified by the introduction of a
N-terminal methyl group to improve the cellular permeability
(Sun et al, 2006), yielding SMAC067 (compound 4b, (Seneci et al,
2009)). As dimeric SMAC-mimetics have been shown to be more
potent than their monomeric counterparts in activating apoptosis
(Li et al, 2004), we synthesised three homodimeric compounds by
coupling two SMAC067 units with different linkers (Supplemen-
tary Figure S2). The affinity of the compounds for XIAP BIR3 and
lkBIR2/BIR3, measured by fluorescent polarisation as described
(Nikolovska-Coleska et al, 2004, 2008) revealed that all three
dimeric compounds had a lower affinity for BIR3 than the
monomers (Table 1), suggesting that the linker region slightly
hinders the interaction with BIR3 in vitro. However, the
interaction of the homodimers with the lkBIR2/BIR3 was 10-fold
higher compared with the monomer. Little differences in affinity
could be detected between the three bivalent compounds towards
BIR3 or lkBIR2/BIR3, with SMAC076 being the best interactor of
both recombinant proteins.
Aside from XIAP, SMAC-mimetics have been shown also to bind
cIAP1 and cIAP2 (Varfolomeev et al, 2007; Vince et al, 2007).
However, in contrast to XIAP, the binding of SMAC-mimetics to
cIAPs induces their rapid auto-ubiquitination and subsequent
proteasomal degradation. To determine whether the newly
developed SMAC-mimetics caused the degradation of cIAP1 and
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Figure 3 Bortezomib sensitises melanoma cells to TRAIL without affecting caspase-8 levels. (A) Cell proliferation evaluated 72h after treatment with 5nM
Bortezomib (4nM for Me1007) or 50ngml
–1 of iz-TRAIL or a combination thereof (MTT assay). The figure is representative of three independent
experiments carried out in triplicate (mean values±s.d.). (B) Levels of full-length caspase-8 or cleaved PARP, caspase-8 and -3 in lysates from melanoma cell
lines treated with Bortezomib for 24h at the indicated doses. (C) Levels of caspase-8 in lysates of Me1007 treated with Bortezomib for 24h at the indicated
doses (nM) and/or pretreated for 1h with 15mM of z-VAD-fmk. Determination of PARP cleavage was used as a control to check activity of z-VAD-fmk
and b-Actin served as loading control.
Table 1 Affinities of newly developed SMAC-mimetics for XIAP BIR3
and lkBIR2BIR3
Compound IC50 BIR3±s.e.% nM IC50 lkBIR23±s.e.% nM
67
a 104±14.2 54±48.5
74 180.5±13.2 5.91±22.2
75 178.8±15.9 3.18±18.4
76 157±13.5 2.27±24.5
Abbreviations: BIR¼baculoviral inhibitor repeats; SMAC¼second mitochondria-
derived activator of caspase; s.e.%¼standard error %; XIAP¼X-linked inhibitor of
apoptosis protein. The affinities of the new SMAC-mimetic compounds were
evaluated by a fluorescent polarisation-based binding assay using increasing
concentrations of SMAC-mimetics, two fluorescent dyes and the recombinant
proteins containing the BIR3 or the lkBIR2BIR3 domains of XIAP as described in
Material and Methods.
aSee Seneci et al (2009).
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scIAP2, we treated the four melanoma cell lines with the monomeric
or dimeric SMAC-mimetics and analysed the effect of treatment on
cIAP1/2 expression. Interestingly, all three dimeric compounds
decreased the levels of cIAP1 and cIAP2 (Figures 4A and B and
data not shown), most effectively in response to SMAC075 and
SMAC076. SMAC067, on the contrary, had little effect, if any, on
cIAP1 and cIAP2 levels. It is noteworthy that Me1007 cells were
negative for the expression of cIAP2 (Figure 4B). Altogether, our
new SMAC-mimetics not only bind XIAP with nanomolar
affinities, but also induce the intracellular degradation of cIAP1
and cIAP2.
SMAC-mimetics synergise with TRAIL
The in vitro synergism of SMAC-mimetics with TRAIL under-
scores the potential of this combination in cancer treatment (Li
et al, 2004; Vogler et al, 2009). As a result of this, we analysed the
synergism of TRAIL with our SMAC-mimetics more thoroughly.
At the doses used here as single agents TRAIL and SMAC-mimetics
had little effect on viability. However, in combination they potently
induced loss of cell viability in all cell lines tested, except Me1007
(Figure 5A). This was associated with a strong activation of the
apoptotic pathway, involving cleavage of caspase-8, activation of
caspase-3 and accumulation of cleaved PARP (Figure 5B). Thus,
cell death was due to apoptosis as this event was also abrogated
by pretreatment with the pan-caspase inhibitor z-VAD-fmk
(Figure 5A). Apoptosis was modest in Me1007, disappearance of
full-length caspase-8 was not accompanied by accumulation of
detectable p41/p43 of caspase-8 (Figure 5B). Nevertheless, a faint
band of cleaved PARP appeared, suggesting that at least in some
cells effector caspase activation had occurred. Western blot
analysis confirmed the potent apoptogenic effect of iz-TRAIL in
combination with SMAC-mimetics as compared with the single
agents, and that the dimeric SMAC-mimetics are more powerful
than the monomeric one in synergising with TRAIL (Figure 5B).
Apoptotic cells were also assessed by flow cytometry analysis of the
sub-G1 peak. The combined treatment of TRAIL with a SMAC-
mimetic (SMAC075) augmented the proportion of the sub-diploid
apoptotic population compared with single and mock treatments
(Supplementary Table S3 and data not shown) in melanoma cells
responsive to these drugs, while the increment was modest in
Me1007.
It is noteworthy that the diverse linkers used have little effect
on SMAC-mimetic activity, in accordance with the affinity for
XIAP in vitro (Table 1) or stimulation of cIAP1/2 degradation
(Figures 4A and B). Hence, our new SMAC-mimetics are able to
inhibit melanoma cell growth by inducing apoptosis in synergism
with iz-TRAIL.
Bortezomib synergises with SMAC-mimetics in melanoma
cell lines resistant to the combined effect of TRAIL/
SMAC-mimetic
As Bortezomib sensitises cells to TRAIL-induced apoptosis at a
different level than SMAC-mimetics, namely at the TRAIL DISC,
we next addressed whether their combination would be synergistic
in sensitising melanoma cells to TRAIL-induced apoptosis.
We first tested the Me1007 cell line, which is poorly responsive
to the TRAIL/SMAC-mimetics (Figure 5A), and found that already
the combination of Bortezomib with dimeric SMAC-mimetics,
induced almost complete loss of cell viability (Figure 6A). By
contrast, the single compounds showed little activity (Figures 5A
and 6A). The loss of cell viability by Bortezomib and SMAC-
mimetics was due to apoptosis as it was accompanied by the
accumulation of cleaved caspase-3 and PARP (Figure 6B), and to
some extent dependent on caspase-8 because its depletion rescued
cells from death triggered by Bortezomib (data not shown).
Conversely, the cell lines sensitive to TRAIL/SMAC-mimetic were
less sensitive to Bortezomib/SMAC-mimetic combination
(Figure 6C and data not shown). As Bortezomib has been shown
to be capable of modulating the expression levels of different
proteins involved in regulating sensitivity to TRAIL (Koschny et al,
2007), we checked the expression of the caspase-8 inhibitor cFLIP.
However, neither Bortezomib nor the SMAC-mimetics or their
combinations affected cFLIP expression (Figure 6B).
These findings indicate that in vitro melanoma cells resistant
to the combination of TRAIL with SMAC-mimetics can be killed
by the combined effects of Bortezomib and SMAC-mimetic. Thus,
the combination of SMAC-mimetics with Bortezomib, previously
shown to kill multiple myeloma cells in vitro (Chauhan et al, 2007),
may also be useful for the treatment of melanoma.
DISCUSSION
X-linked IAP is a pivotal anti-apoptotic regulator, owing to its
capacity to bind and block both initiator and effector caspases
(Deveraux et al, 1997). XIAP is overexpressed in many tumours in
which it confers resistance to chemotherapeutic agents (Li et al,
2004; Oost et al, 2004) and to TRAIL, an apoptosis-inducing
biotherapeutic drug (Walczak et al, 1999) currently tested in
various clinical trials (Ashkenazi and Herbst, 2008; Newsom-Davis
Me1007 Me2211/2
XIAP
β-Actin
cIAP1
76 75 74 67 UN 76 75 74 67 UN 76 75 74 67 UN 76 75 74 67 UN
XIAP
β-Actin
cIAP2
Me1007
76 75 74 67 UN 76 75 74 67 UN
Me4405 Me10538
Me4405
Figure 4 New SMAC-mimetics targeting IAPs. (A) Levels of cIAP1 and XIAP in melanoma cell lines treated for 3h with 500nM of the indicated
compounds or mock-treated (UN). (B) Levels of cIAP2 and XIAP in melanoma cell lines treated for 3h with 500nM of the indicated compounds or mock-
treated (UN). b-Actin served as loading control.
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set al, 2009). Unlike the other apoptosis-inducing ligands of the
TNF superfamily, TNF and CD95L, TRAIL is not toxic for normal
cells, suggesting its potential exploitability for treatment purposes.
In spite of the fact that different members of the IAP family show
high homology and can have redundant roles, nevertheless
XIAP is so far the only member known to affect sensitivity to
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Figure 5 SMAC-mimetics synergise with TRAIL in triggering apoptosis. (A) Cell viability was evaluated 72h after onset of treatment with 500nM
SMAC-mimetic and/or iz-TRAIL used at 50ngml
–1with or without pretreatment with 15mM of z-vad-fmk (MTT assay). The figure is representative of three
independent experiments carried out in triplicate (mean values±s.d.). (B) Levels of caspase-8, cleaved PARP and caspase-3 in cells treated for 24h with
iz-TRAIL at 50ngml
–1 and SMAC-mimetic at 500nM. b-Actin served as loading control.
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sTRAIL-induced apoptosis (Cummins et al, 2004), providing
a rationale for combining TRAIL with drugs targeting XIAP.
In our work, we first treated some melanoma cell lines with
iz-TRAIL, a recombinant TRAIL fused with a synthetic isoleucine
zipper that favours trimerisation, thereby enhancing its activity
(Ganten et al, 2006), a phenomenon we had first reported for a
different version of TRAIL together with an in vivo half-life of
approximately 1h (Walczak et al, 1997). Together, increased
activity because of stable trimer formation and increased half-life
renders isoleucine zipper tagged forms of TRAIL potentially better
drug candidates as we previously showed (Walczak et al, 1999;
Ganten et al, 2004, 2006) and has recently been confirmed by
others (Rozanov et al, 2009). Three melanoma lines were sensitive
to iz-TRAIL at high concentrations but their response could be
amplified by concomitant administration of SMAC-mimetics. By
contrast and in concordance with a previous report (Zhang et al,
2001), the fourth line tested, Me1007, was resistant to iz-TRAIL
treatment, most likely because of caspase-8 expression being too
low to enable activation of the extrinsic apoptosis pathway.
Interestingly, the knock-down of XIAP and, partially, the
simultaneous administration of the new SMAC-mimetic com-
pounds we developed, could restore sensitivity of Me1007 cells to
TRAIL-induced apoptosis. In these cells, low levels of caspase-8
could probably activate little caspase-3 that XIAP keeps in check
preventing the apoptosis cascade, but when XIAP is targeted, the
levels of caspase-3 might become enough to trigger apoptosis.
Interestingly, in presence of downregulated levels of XIAP, there
is an accumulation of the cleaved p43 and p41 forms of caspase-8,
both in melanoma and mammary carcinoma cell lines. XIAP could
influence this event in two ways, directly by ubiquitinating the
cleaved form of caspase-8 and causing its degradation, or
indirectly by blocking caspase-3, which was previously shown to
cleave caspase-8 (Wieder et al, 2001; Lee et al, 2005; Hayakawa
et al, 2008). As XIAP was shown to interact with caspases 3, 7 and
9, but not 8 (Deveraux et al, 1998), it is unlikely that the
accumulation of the p43/41 forms of caspase-8 is caused directly
by XIAP. More likely, XIAP, by inhibiting caspase-3, prevents its
positive feedback loop, by which caspase-8 is further cleaved
(Wieder et al, 2001; Lee et al, 2005; Hayakawa et al, 2008). Thus,
lower levels of XIAP allow the accumulation of the cleaved form of
caspase-8.
SMAC-mimetics have been shown to activate apoptosis also as
stand-alones in a few cell lines (Petersen et al, 2007). This
mechanism is independent from their activity on XIAP, and
rather because of their capacity of targeting cIAP1 and cIAP2
(Varfolomeev et al, 2007; Vince et al, 2007). In this case,
SMAC-mimetics do not trigger apoptosis by displacing caspases
from XIAP, but by inducing TNF and rendering cancer cells
sensitive to autocrine TNFa (Varfolomeev et al, 2007; Vince et al,
2007; Bertrand et al, 2008). According to this, the apoptotic
pathway depends on caspase-8 presence, but is not influenced
by XIAP levels (Gaither et al, 2007). Indeed, the new dimeric
SMAC-mimetics we present here are able to trigger rapid and
complete degradation of cIAP1, and, consequently, to cause
apoptosis in MDA-MB231 cells as single agents (data not shown).
Nevertheless, SMAC-mimetics are more widely utilisable in
association with other drugs to favour their activity (Li et al, 2004).
In this study, we show that the newly developed SMAC-mimetics
can facilitate the apoptotic cascade stimulated by TRAIL,
rendering melanoma cells, which are notoriously resistant to
chemotherapy, more sensitive to this ligand. Interestingly, the
Me1007 cell line, resistant to SMAC-mimetic/TRAIL, became
extremely sensitive to the combination of SMAC-mimetics and
Bortezomib, the latter widely used in cancer therapy. This
observation raises the possibility that SMAC-mimetics could be
useful in combination with diverse drugs.
In conclusion, SMAC-mimetics targeting members of the IAP
family, especially XIAP, offer a new strategy for the treatment of
chemotherapy-resistant melanomas, particularly when used in
combination with other drugs like Bortezomib, TRAIL or TRAIL-R
agonists.
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Figure 6 SMAC-mimetics synergise with Bortezomib in triggering
apoptosis in Me1007 cells. (A) Me1007 cell viability was evaluated 72h
after treatment with 500nM SMAC-mimetic and/or Bortezomib 4nM (MTT
assay). The figure is representative of three independent experiments in
triplicate (mean values±s.d.). (B) Levels of cleaved PARP and caspase-3,
and cFLIP in cells treated for 24h with Bortezomib at 4nM and SMAC-
mimetics at 500nM. b-Actin served as loading control. The asterisk indicates
a nonspecific band. (C) Me2211M2 cell viability was evaluated 72h after
treatment with 500nM SMAC076 and/or Bortezomib 5nM (MTT assay).
The figure is representative of two independent experiments carried out in
triplicate (mean values±s.d.).
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